Video

Dr. Ganly on a Postoperative Nomogram for Predicting Cancer-Specific Mortality in MTC

Ian Ganly, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in MTC.

Ian Ganly, MD, PhD, head and neck surgeon, Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in patients with medullary thyroid cancer (MTC).

Survival outcomes are influenced by numerous factors, including stage at presentation and the ability to resect all of the disease. Ganly says the aim of the project was to design a model that incorporates clinical, pathological, and biochemical variables to determine cancer-specific mortality.

The statistical model was designed by using regression analysis. The result was a nomogram, which could be used to predict outcomes, Ganly says. The nomogram consisted of 7 factors that are the most predictive of outcomes. These factors included TNM status, age, gender, vascular invasion, and postoperative calcitonin levels.

The nomogram had a concordance index of 0.77, Ganly says. However, the nomogram was only developed using data from 250 patients and needs to be validated in other populations at other institutions.

<<<

View more from the 2014 ATA Annual Meeting

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center